189 related articles for article (PubMed ID: 26358708)
41. Hormone receptor-negative breast cancer: undertreatment of patients over 80.
Weiss A; Noorbakhsh A; Tokin C; Chang D; Blair SL
Ann Surg Oncol; 2013 Oct; 20(10):3274-8. PubMed ID: 23838924
[TBL] [Abstract][Full Text] [Related]
42. Factors associated with mortality after breast cancer metastasis.
Jung SY; Rosenzweig M; Sereika SM; Linkov F; Brufsky A; Weissfeld JL
Cancer Causes Control; 2012 Jan; 23(1):103-12. PubMed ID: 22037907
[TBL] [Abstract][Full Text] [Related]
43. Moderate level of HER2 expression and its prognostic significance in breast cancer with intermediate grade.
Ignatov T; Eggemann H; Burger E; Fettke F; Costa SD; Ignatov A
Breast Cancer Res Treat; 2015 Jun; 151(2):357-64. PubMed ID: 25926338
[TBL] [Abstract][Full Text] [Related]
44. De-novo metastatic breast cancers with or without primary tumor resection - A 10-year study.
Co M; Ng J; Kwong A
Cancer Treat Res Commun; 2019; 19():100118. PubMed ID: 30825858
[TBL] [Abstract][Full Text] [Related]
45. Progesterone receptor status in determining the prognosis of estrogen receptor positive/ HER2 negative breast carcinoma patients.
Bal O; Yalcintas Arslan U; Durnali A; Uyetrk U; Demirci A; Tastekin D; Ekinci A; Esbah O; Turker I; Uysal Sonmez O; Oksuzoglu B
J BUON; 2015; 20(1):28-34. PubMed ID: 25778292
[TBL] [Abstract][Full Text] [Related]
46. Comparison of patterns and prognosis among distant metastatic breast cancer patients by age groups: a SEER population-based analysis.
Chen MT; Sun HF; Zhao Y; Fu WY; Yang LP; Gao SP; Li LD; Jiang HL; Jin W
Sci Rep; 2017 Aug; 7(1):9254. PubMed ID: 28835702
[TBL] [Abstract][Full Text] [Related]
47. Patterns of
Xiao Q; Zhang W; Jing J; Zhong T; Li D; Zhou J; Liu P; Duan Z; Gao H; Shen L
Front Endocrinol (Lausanne); 2023; 14():1184895. PubMed ID: 38027167
[TBL] [Abstract][Full Text] [Related]
48. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer.
Stemmler HJ; Kahlert S; Siekiera W; Untch M; Heinrich B; Heinemann V
Breast; 2006 Apr; 15(2):219-25. PubMed ID: 16026983
[TBL] [Abstract][Full Text] [Related]
49. Brain metastases in breast cancer: prognostic factors and management.
Lee SS; Ahn JH; Kim MK; Sym SJ; Gong G; Ahn SD; Kim SB; Kim WK
Breast Cancer Res Treat; 2008 Oct; 111(3):523-30. PubMed ID: 17990100
[TBL] [Abstract][Full Text] [Related]
50. Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
Finn RS; Press MF; Dering J; O'Rourke L; Florance A; Ellis C; Martin AM; Johnston S
Clin Cancer Res; 2014 Feb; 20(3):736-43. PubMed ID: 24198242
[TBL] [Abstract][Full Text] [Related]
51. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?
Dawood S; Broglio K; Valero V; Reuben J; Handy B; Islam R; Jackson S; Hortobagyi GN; Fritsche H; Cristofanilli M
Cancer; 2008 Nov; 113(9):2422-30. PubMed ID: 18785255
[TBL] [Abstract][Full Text] [Related]
52. Use of trastuzumab for HER2-positive metastatic breast cancer in daily practice: a population-based study focusing on the elderly.
van Rooijen JM; de Munck L; Teeuwen GM; de Graaf JC; Jansman FG; Boers JE; Siesling S
Anticancer Drugs; 2016 Feb; 27(2):127-32. PubMed ID: 26473525
[TBL] [Abstract][Full Text] [Related]
53. First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer.
Peron J; Tredan O; Ray-Coquard I; Bachelot T; Labidi Galy SI; Favier B; Treilleux I; Guastalla JP
Bull Cancer; 2012 Feb; 99(2):E18-25. PubMed ID: 22257781
[TBL] [Abstract][Full Text] [Related]
54. The effect of delays in treatment for breast cancer metastasis on survival.
Jung SY; Sereika SM; Linkov F; Brufsky A; Weissfeld JL; Rosenzweig M
Breast Cancer Res Treat; 2011 Dec; 130(3):953-64. PubMed ID: 21739101
[TBL] [Abstract][Full Text] [Related]
55. Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression.
Balduzzi A; Bagnardi V; Rotmensz N; Dellapasqua S; Montagna E; Cardillo A; Viale G; Veronesi P; Intra M; Luini A; Pruneri G; Mastropasqua G; Goldhirsch A; Colleoni M
Clin Breast Cancer; 2014 Aug; 14(4):258-64. PubMed ID: 24325948
[TBL] [Abstract][Full Text] [Related]
56. Metastatic pattern discriminates survival benefit of primary surgery for de novo stage IV breast cancer: A real-world observational study.
Wang K; Shi Y; Li ZY; Xiao YL; Li J; Zhang X; Li HY
Eur J Surg Oncol; 2019 Aug; 45(8):1364-1372. PubMed ID: 30837102
[TBL] [Abstract][Full Text] [Related]
57. Factors Associated with Early Mortality Among Patients with
Vaz-Luis I; Lin NU; Keating NL; Barry WT; Winer EP; Freedman RA
Oncologist; 2017 Apr; 22(4):386-393. PubMed ID: 28242790
[TBL] [Abstract][Full Text] [Related]
58. Comparison between de novo and metachronous metastatic breast cancer: the presence of a primary tumour is not the only difference-a Dutch population-based study from 2008 to 2018.
de Maar JS; Luyendijk M; Suelmann BBM; van der Kruijssen DEW; Elias SG; Siesling S; van der Wall E
Breast Cancer Res Treat; 2023 Apr; 198(2):253-264. PubMed ID: 36648694
[TBL] [Abstract][Full Text] [Related]
59. Survival of de novo stage IV breast cancer patients over three decades.
Hölzel D; Eckel R; Bauerfeind I; Baier B; Beck T; Braun M; Ettl J; Hamann U; Harbeck N; Kiechle M; Mahner S; Schindlbeck C; de Waal J; Engel J
J Cancer Res Clin Oncol; 2017 Mar; 143(3):509-519. PubMed ID: 27853869
[TBL] [Abstract][Full Text] [Related]
60. The prognostic significance of metastatic pattern in stage IV male breast cancer at initial diagnosis: a population-based study.
Leone JP; Leone BA; Zwenger AO; Vallejo CT; Romero AO; Machiavelli MR; Pérez JE; Leone J
Breast Cancer Res Treat; 2021 May; 187(1):237-244. PubMed ID: 33389398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
